Venetoclax as a single agent and in combination with PI3K-MTOR1/2 kinase inhibitors against ibrutinib sensitive and resistant mantle cell lymphoma.

ABSTRACT:

SUBMITTER: Jiang H 

PROVIDER: S-EPMC6066460 | biostudies-literature | 2019 Jan

REPOSITORIES: biostudies-literature